-
1 week ago | 
idse.net | Marie Rosenthal
By Marie Rosenthal, MSThe total number of measles cases as of May is more than three times higher than previously reported all of last year. As of May 1, 2025, a total of 935 cases of measles have been confirmed by 30 jurisdictions in the United States; by Dec. 31, 2024, a total of 285 measles cases were reported by 33 jurisdictions.
-
2 weeks ago | 
painmedicinenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionMore data from the STOMP (Study of Tecovirimat for Mpox) trial presented at CROI 2025, in San Francisco, confirmed that tecovirimat does not reduce the time to clinical resolution of clade II mpox lesions or improve pain among adults, according to Timothy Wilkin, MD, MPH, a professor of medicine and the chief of the Division of Infectious Diseases and Global Public Health at the University of
-
3 weeks ago | 
pharmacypracticenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSThe CDC’s Advisory Committee on Immunization Practices voted to recommend the virus-like particle-based chikungunya vaccine, recombinant (CHIK-VLP; Vimkunya, Bavarian Nordic) for certain populations. However, the CDC has not acted yet on this or other recommendations the ACIP made April 16.
-
3 weeks ago | 
pharmacypracticenews.com | Marie Rosenthal
Ensitrelvir, an antiviral being developed to prevent COVID-19, reduced the risk of developing the infection by 67% in uninfected people after exposure to SARS-CoV-2 compared with placebo at day 10, according to results presented at CROI 2025, held in San Francisco (abstract 200). The 67% reduction is “super exciting,” said Diane Havlir, MD, the CROI chair, and the chief of the HIV, Infectious Diseases and Global Medicine Division at Zuckerberg San Francisco General Hospital and Trauma Center.
-
4 weeks ago | 
pharmacypracticenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSThe CDC’s Advisory Committee on Immunization Practices (ACIP) recommended the use of meningococcal groups A, B, C, W and Y vaccine (MenABCWY; Penmenvy, GSK) as part of the adolescent meningococcal vaccination schedule to protect against disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y). On Feb.
-
1 month ago | 
pharmacypracticenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSIn a unanimous vote, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus vaccines to adults 50 to 59 years of age at increased risk for RSV-associated lower respiratory tract disease (LRTD). This includes people with conditions such as chronic obstructive pulmonary disease (COPD), asthma,
-
1 month ago | 
idse.net | Marie Rosenthal
By Marie Rosenthal, MSIn a unanimous vote, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus vaccines to adults 50 to 59 years of age at increased risk for RSV-associated lower respiratory tract disease (LRTD). This includes people with conditions such as chronic obstructive pulmonary disease (COPD), asthma, diabetes, cardiovascular disease and those in residential care.
-
1 month ago | 
pharmacypracticenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSA higher clinical cure rate was found among patients with serious gram-negative bacterial infections who received cefiderocol (Fetroja, Shionogi) as empiric therapy or for a documented infection than among those given it as salvage therapy, according to a presentation at ESCMID Global 2025, in Vienna (poster P2542).
-
1 month ago | 
specialtypharmacycontinuum.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSIf given within 72 hours after clinical onset of COVID-19 in a household, oral ensitrelvir was effective in protecting household contacts from SARS-CoV-2 infection, according to a presentation at ESCMID Global 2025, in Vienna (abstract 03159). Protection was consistently seen in all at-risk groups studied, including older household contacts, according to Frederick G. Hayden, MD, the Stuart S.
-
1 month ago | 
pharmacypracticenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSIf given within 72 hours after clinical onset of COVID-19 in a household, oral ensitrelvir was effective in protecting household contacts from SARS-CoV-2 infection, according to a presentation at ESCMID Global 2025, in Vienna (abstract 03159). Protection was consistently seen in all at-risk groups studied, including older household contacts, according to Frederick G. Hayden, MD, the Stuart S.
